[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-prevention":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,79,101,125,150,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100605424","bile-acid-gut-microbiome-axis-modification-through-diet-education-for-colorectal-cancer-prevention-100605424",false,"NCT07162337","BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention","BILMOD: BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention","BILMOD","Inclusion Criteria:\n\n* Underwent screening or surveillance colonoscopy with removal of at least one adenoma.\n* Age 18-80 years.\n* Habitually consume a Western pattern diet.\n* BMI of at least 18.5 kg\u002Fm2 but less than 35 kg\u002Fm2\n* Weight stable in last 3 months (loss or gain \\\u003C4%).\n* Subjects must be able and willing to follow study procedures and instructions.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.).\n* Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.\n* Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years.\n* Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).\n* Any adenoma that was not completely removed during previous colonoscopy.\n* Known bleeding tendency\u002Fcondition (e.g. von Willebrand disease) or history of peptic ulcer or gastrointestinal bleed requiring hospitalization, endoscopic complications, or contraindication to colonoscopy.\n* Current use of anticoagulant therapies, including Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin\u002FDextrose, and an unwillingness or inability to discontinue anticoagulants.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Regular use of aspirin.\n* Use of antibiotics or probiotics.\n* Inability or unwillingness to abstain from limited consumption of animal-based food or to provide blood or stool samples during the study.\n* Participants who are receiving any other investigational agents.\n* Pregnant or breastfeeding.\n* Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.","ALL","18 Years","80 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer.",[28,29],"Colorectal Cancer Prevention","Colorectal Adenoma",[31,32,33,34,35],"colorectal cancer","colorectal cancer prevention","colorectal adenoma","obesity","western diet","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":37,"type":40},{"date":43,"type":22},"2028-06-01",{"name":45,"class":46},"Massachusetts General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100579674","lifestyle-intervention-among-participants-of-the-french-colorectal-cancer-screening-program-life-screen-100579674","NCT06827366","Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program (LIFE-SCREEN)","LIFE-SCREEN","Inclusion Criteria:\n\n* Having read the information note and agreeing to participate\n* Will and availability to be committed for a full year\n* At high risk for CRC but CRC negative\n* Affiliated to a health security system\n* Having a score on the adherence to the recommendation lower than or equal to 7 out of 9 at baseline.\n* Able to read, write and understand French\n\nExclusion Criteria:\n\n* Under a strict diet such as meal replacements, diets for co-morbidities such as diabetes\n* Immobile due to physical constraints (e.g. handicap that is not compatible with physical activities)\n* Extensive intestinal surgery such as colectomy or surgical resection of the colon\n* Chronic gastrointestinal illness (IBD, IBS, celiac disease)\n* Colorectal cancer confirmed or history of a primary cancer\n* Severe malnutrition\n* Pregnant\n* Participation in another lifestyle study\n\nNB : For this study, there is no exclusion period from other research, and participants can simultaneously take part in another study unless it concerns lifestyle.","35 Years","74 Years",{"count":58,"type":22},800,[25],"The investigators propose a randomized controlled trial to develop and evaluate the impact of promoting advice on diet and lifestyle recommendations for cancer prevention at colorectal cancer screening among individuals who may be at higher risk for colorectal cancer (CRC). The specific objectives of this study are to 1) develop a lifestyle intervention based on evidenced-based diet and lifestyle recommendations (i.e. those proposed by the World Cancer Research Fund (WCRF) and the French National Cancer Institute); 2) evaluate the effect of the intervention on the adherence to the target diet and lifestyle recommendations as well as other subjective health measures, including quality of life; 3) evaluate the effect of the intervention on anthropometrics.",[62,28,63],"Colorectal Cancer Screening","Colorectal Cancer",[31,65,66,67,68,69],"primary prevention","screening","physical activity","nutrition","recommendations","2026-04-29",{"date":72,"type":40},"2026-05-05",{"date":74,"type":40},"2026-01-26",{"date":76,"type":22},"2028-02-15",{"name":78,"class":46},"Centre Leon Berard",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100623228","colorectal-cancer-prevention-research-study-eat-right-screen-right-100623228","NCT07393906","Colorectal Cancer Prevention Research Study: Eat Right, Screen Right","Eat Right, Screen Right: A Web-based, Self-paced Nutrition Risk Module and Cancer Prevention Resource","Inclusion Criteria:\n\n* 18 years or older\n* Able to understand English\n* Access to a computer or mobile device\n\nExclusion Criteria:\n\n* 17 years or younger\n* Unable to understand English\n* No access to a computer or mobile device",true,{"count":88,"type":22},200,[25],"The Eat Right, Screen Right Extension program aims to help adult learners manage nutrition risks and screening options for colorectal cancer prevention. Participants navigate through 6 tailored lessons covering user-identified, evidence-based information relevant to reducing colorectal cancer risk. First, participants receive an overview of colorectal cancer screening guidelines (e.g., age, modalities), personalized nutrition risk factors (e.g., how their intake of red meat, processed meat, and alcohol aligns with nutrition guidelines for colorectal cancer prevention), and additional optional colorectal cancer prevention topics via a branched conversational pathway selected by the participant. Subsequently, participants also have the opportunity to access five additional modules, providing more in-depth information. Self-reported outcomes include changes in cancer information overload, dietary intentions, and cancer screening intentions. This is an extension of previously funded pilot study and aims to enhance reach by leveraging the UF\u002FIFAS Extension infrastructure allowing participants to achieve the following goals: (1) demonstrate accurate understanding of the modifiable dietary behavior that decrease colorectal cancer risk, (2) demonstrate understanding of screening guidelines and several ways to screen for colorectal cancer (e.g., home stool tests, colonoscopy, others), (3) develop confidence to obtain colorectal cancer screening and stay up to date with screening based on guidelines, (4) apply behavior change strategies to support cancer prevention behaviors.",[28],"2026-04-16",{"date":94,"type":40},"2026-04-22",{"date":96,"type":40},"2026-01-07",{"date":98,"type":22},"2028-02",{"name":100,"class":46},"University of Florida",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100600286","phase-1-pathways-risk-factors-and-molecules-to-prevent-early-onset-colorectal-tumors-100600286","NCT07095517","Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","PROSPECT","Inclusion Criteria:\n\n* Age 18-50 years Because no dosing or adverse event data are currently available on the use of tirzepatide in participants \\\u003C18 years of age, children are excluded from this study. Because we are specifically studying the prevention of EOCRC, which is defined as CRC occurring prior to age 50, the study population will only enroll participants under the age of 50 at baseline.\n* BMI between 27 and 40 kg\u002Fm2\n* Underwent a screening or surveillance colonoscopy within the prior 9 months.\n* Removal of multiple (at least 2) colon or rectal adenomas (including sessile serrated adenomas but excluding hyperplastic polyps) or a single adenoma ≥6mm in size during the last colonoscopy\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have ever taken incretin mimetic therapies.\n* Participants with a history of medullary thyroid cancer or MEN 2 syndrome.\n* Participants at high risk of pancreatitis or otherwise contraindicated for use of tirzepatide according to clinical labeling.\n* Participants with a history of cancer (excluding non-melanoma skin) within the last three years\n* Participants with a history of diabetes mellitus\n* Participants with a history of bowel surgery\n* Participants with hereditary cancer syndromes, including HNPCC\u002FLynch syndrome or familial adenomatous polyposis\n* Participants with a history of inflammatory bowel disease, Crohn's, or colitis.\n* Participants with incomplete or partial polypectomy during prior colonoscopy.\n* Participants who are pregnant. Participants who may become pregnant or partners of those who may become pregnant while on study will receive contraception counseling. Participants or partners of those who become pregnant while participating on the study should immediately inform their doctor.","50 Years",{"count":110,"type":22},20,[112],"PHASE1","This research study is an open-label Phase 1 Exploratory\u002FPilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.",[28,29],[31,32,33,34,116],"incretin mimetics","2026-02-25",{"date":119,"type":40},"2026-02-27",{"date":121,"type":40},"2026-02-24",{"date":123,"type":22},"2028-12-31",{"name":45,"class":46},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":47},"100620742","study-comparing-the-quality-of-colon-cleanliness-with-prepackaged-lrd-low-residue-diet-vs-guided-pog-100620742","NCT07361575","Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).","A Single-blind, Randomized Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).","POG","Inclusion Criteria:\n\n* Patient of one of the investigators for total colonoscopy (no prior colonic surgery);\n* Patient aged 18 years or older;\n* Patient classified as ASA 1, ASA 2, or ASA 3;\n* Not participating in any other current clinical trial;\n* Free, informed, and signed consent;\n* Patient affiliated with or a beneficiary of a social security scheme, according to Article L.1124-1 of the French Public Health Code;\n\nExclusion Criteria:\n\n* Patient taking major psychotropic medications;\n* Patient with uncontrolled diabetes;\n* Patient with coagulation abnormalities preventing polypectomy: PT \\\u003C50%, Platelets \\\u003C50,000\u002Fmm³, current effective anticoagulation therapy (clopidogrel, prasugrel, or ticagrelor);\n* Patient referred for removal of a known polyp;\n* Chronic inflammatory bowel disease;\n* Known colonic stenosis;\n* Diverticulitis of less than 6 weeks duration;\n* Pregnant, parturient, or breastfeeding woman;\n* Patient deprived of liberty by administrative or judicial order, or under guardianship or limited legal protection;\n* Patient unable to understand the objectives and constraints of the study.",{"count":134,"type":22},230,[25],"Low-residue diet (LRD) in patient improves the quality of the colon cleanliness and thus the adenoma detection rate (ADR). This is a key criterion in colonoscopy screening for colorectal cancer (CRC). The benefit of an LRD lasting more than 24 hours before colonoscopy has not been demonstrated compared to a 24-hour LRD.\n\nFew studies have evaluated the benefit of a prepackaged 24-hour LRD compared to simply receiving oral and written LRD instructions during a consultation.\n\nThe aim of the study is to evaluate the usefulness of a prepackaged LRD (Colobox®) compared to simple LRD instructions on colon cleanliness (Boston score) in patients examined by endoscopy.",[28,138,139],"Colorectal Cancer (Diagnosis)","Colorectal Adenocarcinoma","NOT_YET_RECRUITING","2026-02-13",{"date":143,"type":40},"2026-02-17",{"date":145,"type":22},"2026-01-30",{"date":147,"type":22},"2026-11-30",{"name":149,"class":46},"Clinique Paris-Bercy",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100622077","ultra-high-risk-surveillance-to-avoid-future-events-the-ultra-safe-trial-100622077","NCT07378930","ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial","ULTRA-SAFE","Inclusion Criteria:\n\n1. Age: Adults aged 40 to 75 years.\n2. Initial Colonoscopy Findings: Detection and removal of at least two advanced adenomas during the baseline colonoscopy.\n3. Adherence: Willingness to comply with the assigned screening protocol, including fecal immunochemical testing (FIT) and follow-up colonoscopies\n\nExclusion Criteria:\n\n1. Age: Individuals younger than 40 or older than 75 years.\n2. High-Risk Predispositions: Patients with inflammatory bowel disease (IBD), Familial Adenomatous Polyposis (FAP), or a documented hereditary colorectal cancer syndrome (e.g., Lynch syndrome).\n3. Cancer History: A history of colorectal cancer (excluding carcinoma in situ).\n4. Contraindications: Patients for whom polypectomy is clinically inappropriate or unsafe.\n5. Adenoma Count\u002FType: Failure to meet the requirement of at least two advanced adenomas during the initial colonoscopy.\n\n7.Extensive Low-Risk Lesions: Presence of more than ten low-risk adenomas.\n\n8.Pregnancy: Currently pregnant individuals.","40 Years","75 Years",{"count":160,"type":22},940,[25],"The ULTRA-SAFE clinical trial is a prospective, randomized study designed to address the limitations of current \"one-size-fits-all\" colorectal cancer surveillance guidelines. While international standards recommend a three-year follow-up colonoscopy for all high-risk patients, data suggests that those with multiple advanced adenomas face a significantly higher recurrence risk (20%) compared to those with only low-risk adenomas (9%). To provide more personalized care, the trial compares a Standard Arm (colonoscopy at year three) against a FIT Arm, where participants undergo annual fecal immunochemical testing in years one and two. A positive FIT triggers an earlier colonoscopy, with the goal of reducing the 3-year prevalence of metachronous advanced colorectal neoplasms (meta-ACRN) from 20% to approximately 12.7%. The study has enrolled roughly 940 participants to statistically validate whether this early screening intervention can effectively prevent future malignant events in ultra-high-risk populations.",[164,28,165],"Colorectal Neoplasms","Surveillance Colonoscopy",[167,168,169,170],"Colonoscopy surveillance","Colorectal cancer prevention","Post-polypectomy surveillance","Fecal immunochemical test","2026-01-23",{"date":145,"type":40},{"date":174,"type":22},"2026-03-01",{"date":176,"type":22},"2031-05-01",{"name":178,"class":46},"National Taiwan University Hospital",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":47},"100541865","prophylactic-properties-of-carrot-juice-in-patients-with-high-risk-colorectal-polyps-100541865","NCT06335420","Prophylactic Properties of Carrot Juice in Patients With High-Risk Colorectal Polyps","Polyp Prophylactic Properties of Polyacetylenes in Patients With Previous Polypectomy","Px7","Inclusion Criteria:\n\n1. Any type of resection for adenomas larger than 20 mm in size (endoscopically evaluated) or endoscopically resected T1 cancers.\n2. Acceptance of the treatment and follow-up program.\n3. Capability to understand and follow the instructions.\n\nExclusion Criteria:\n\n1. Patients allocated to \"high-risk\" group because of many small polyps (\\>4).\n2. Pregnancy.\n3. Known relevant allergies.\n4. Chronic consumption of COX (cyclooxygenase) inhibitors (Aspirin, Celecoxib, Ibuprofen, Diclofenac, Ketoprofen, Ketorolac, Indometacin, Naproxen, Piroxicam) or immunosuppressive agents (Methotrexate, Azathioprine or glucocorticoids).\n5. Patients with different neoplastic disease under treatment (Chemo-\u002FRadio-\u002FImunotherapy).\n6. Severe comorbidity NYHA III-IV.\n7. Lynch syndrome.",{"count":188,"type":22},400,[25],"The goal of this prospective randomized double-blinded bi-national study is to test the prophylactic effect of polyacetylenes from carrots on the population of patients who had a resection of high-risk adenomas of the large bowel.\n\nThe main question it aims to answer is: Will carrot juice rich in polyacetylenes inhibit neoplastic transformation and growth in high-risk humans?\n\nParticipants will have to drink 100 ml of juice daily after the adenoma resection for 1 year and keep a simple diary\u002Fcalendar.\n\nResearchers will compare the group with ingestion of Falcarinol (FaOH) \u002F Falcarindiol (FaDOH) rich carrot juice versus the group consuming placebo juice, to see if the polyacetylenes significantly reduces neoplastic transformation and growth in high-risk patients.",[28],"2025-11-17",{"date":194,"type":40},"2025-11-20",{"date":196,"type":40},"2024-06-20",{"date":198,"type":22},"2027-12-01",{"name":200,"class":46},"Odense University Hospital"]